November 9, 2008New England Journal of Medicine6,715 citationsOpen Access
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
View Full Paper
Key Points
- Cardiovascular events significantly decrease with statin treatment in those with elevated high-sensitivity C-reactive protein levels.
- Statin therapy reduced high-sensitivity C-reactive protein alongside cholesterol, potentially improving heart health.
- Assessment focuses on high-sensitivity C-reactive protein in relation to cardiovascular risk, indicating a need for targeted treatment strategies and further exploration of inflammation's role in heart health patterns within diverse populations. Highlights the importance of early intervention in inflammatory states to mitigate cardiovascular risks.
Abstract
Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment.
Expert Takes9 quotes
1/9
“That is a larger reduction in the things that we care the most about — morbidity and mortality — than we've ever seen in a statin trial. And it occurred very quickly, in only 1.9 years of average duration of treatment.”
Steven Nissen, Chair of cardiovascular medicine, Cleveland ClinicCleveland Clinicauto_pipelineSupportiveView source
Cite This Study
Ridker et al. (2008) studied this question.